unresectable stage III/IV melanoma MedDRA version: 14.1 Level: HLT Classification code 10027156 Term: Skin melanomas (excl ocular) System Organ Class: 100000004864
Conditions
Interventions
Product Name: dabrafenib
Product Code: GSK2118436
Pharmaceutical Form: Capsule
INN or Proposed INN: Dabrafenib
CAS Number: 1195765-45-7
Current Sponsor code: GSK2118436
Other descriptive name: DABRAF
Sponsors
NKI-AVL
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients have provided signed informed consent. 2. Patients have unresectabel stage III melanoma (documented and based on MSD) or stage IV melanoma with = 3 resectable metastases/organ site. 3. Patients have pathologically confirmed BRAF mutation-positive (V600E/K) melanoma as determined via in-house testing with a BRAF mutation assay. 4. Patients are treatment naïve for unresectable melanoma. 5. Patients for whom the intended operation is considered to offer a chance of cure or substantial palliation. 6. Patients have evaluable disease by CT/MRI or PET with = 3 metastases/organ sites. 7. Patients are =18 years of age. 8. Patients are able to swallow and retain oral medication. 9. Women with child-bearing potential and men with reproductive potential must be willing to practice acceptable methods of birth control during the study. 10. Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to the first dose of study treatment. 11. Patients have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1. 12. Patients must have adequate organ function as defined in the protocol. Treatment with transfusion, growth factors to meet eligibility criteria will not be allowed. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 20 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 5
Exclusion criteria
Exclusion criteria: 1. Patients with known ocular or primary mucosal melanoma. 2. Patients who used any investigational anti-cancer or other drug within 28 days or 5 half-lives, whichever is longer, preceding the first dose of dabrafenib + trametinib. 3. Patients who currently use a prohibited medication or are expected to require any of these medications during treatment with dabrafenib and trametinib. 4. Patients who had any major surgery, radiotherapy, or immunotherapy within the last 4 weeks. 5. Patients with active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs. 6. Patients with a history of glucose-6-phosphate dehydrogenase (G6PD) deficiency. 7. Patients with a history of other malignancy. Subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible 8. Patients with a history of alcohol or drug abuse within 6 months prior to screening. 9. Patients with psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol, or unwillingness or inability to follow the procedures required in the protocol. 10. Patients with the cardiac abnormalities as defined in the protocol. 11. Pregnant or lactating female. 12. Patients with CNS metastases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Primary objectives: To assess the ability of dabrafenib + trametinib treatment to downsize melanoma tumor masses to enable R0-resection. ;Secondary Objective: Secondary objectives: Recurrence free survival; time-to-next treatment, overall survival.;Primary end point(s): The primary endpoint of this study is the % of patients in whom an R0-resection could be performed. This is measured by the pathologist, who handles the resection material (no positive margins) and negative CT-scans. Patients that develop a CR on systemic treatment will of course be included in the analysis. The aim of the study is to enable R0 resection.;Timepoint(s) of evaluation of this end point: 8 weeks after start study treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): As the secondary endpoint recurrence-free survival will be assessed every 3 months by physical exam and CT-scan for 2 years, thereafter every 6 months for 2 year, and once in year 5. Thereafter by physical exam only. This will be assessed only in patients that undergo radical surgery. For patients not undergoing surgery, PFS will be assessed. Time to next treatment is defined as the moment the study treatment starts until start of any following treatment (surgery, RT or systemic treatment) for new lesions. This will be measured in all patients, but patients will be stratified for undergoing surgery or not undergoing surgery. Overall survival will be measured using Kaplan-Meier estimation for the total group of patients as well, again stratified for patients undergoing surgery or no surgery.;Timepoint(s) of evaluation of this end point: During follow-up of the patient. | — |
Countries
Netherlands
Contacts
Public ContactCRA
NKI-AVL
Outcome results
None listed